{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:34:19Z","timestamp":1793658859615,"version":"4.5.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T00:00:00Z","timestamp":1471910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.eururo.2016.08.037","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T12:47:43Z","timestamp":1473425263000},"page":"417-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":212,"title":["DNA Repair in Prostate Cancer: Biology and Clinical Implications"],"prefix":"10.1016","volume":"71","author":[{"given":"Joaquin","family":"Mateo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Boysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.08.037_bib0370","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","article-title":"Sequencing of agents in castration-resistant prostate cancer","volume":"16","author":"Lorente","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0375","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0380","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0385","first-page":"2","article-title":"Genomic correlates to the newly proposed grading prognostic groups for prostate cancer","volume":"69","author":"Rubin","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0390","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2016.08.037_bib0395","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2016.08.037_bib0400","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2016.08.037_bib0405","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2016.08.037_bib0410","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv315","article-title":"BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers","volume":"108","author":"Meeks","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2016.08.037_bib0415","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Beltran","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0420","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2016.08.037_bib0425","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2016.08.037_bib0430","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0435","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0440","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2016.08.037_bib0445","first-page":"241","article-title":"Human DNA repair genes","volume":"1284","author":"Wood","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.eururo.2016.08.037_bib0450","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1128\/MCB.25.16.7158-7169.2005","article-title":"Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks","volume":"25","author":"Saleh-Gohari","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0455","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2016.08.037_bib0460","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2016.08.037_bib0465","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cell.2009.11.030","article-title":"Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer","volume":"139","author":"Lin","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2016.08.037_bib0470","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1126\/science.1127196","article-title":"A topoisomerase II\u03b2-mediated dsDNA break required for regulated transcription","volume":"312","author":"Ju","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.eururo.2016.08.037_bib0475","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/gcc.21999","article-title":"Poly-gene fusion transcripts and chromothripsis in prostate cancer","volume":"51","author":"Wu","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.eururo.2016.08.037_bib0480","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.eururo.2016.08.037_bib0485","first-page":"2009","article-title":"Induced chromosomal proximity and the genesis of gene fusions in prostate cancer","volume":"326","author":"Mani","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.eururo.2016.08.037_bib0490","doi-asserted-by":"crossref","first-page":"e09207","DOI":"10.7554\/eLife.09207","article-title":"SPOP mutation leads to genomic instability in prostate cancer","volume":"4","author":"Boysen","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.eururo.2016.08.037_bib0495","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/ncomms5988","article-title":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","volume":"5","author":"Pritchard","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2016.08.037_bib0500","first-page":"4112","article-title":"Defects of DNA mismatch repair in human prostate cancer","volume":"61","author":"Chen","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.08.037_bib0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajhg.2016.03.003","article-title":"Biallelic BRCA2 mutations shape the somatic mutational landscape of aggressive prostate tumors","volume":"98","author":"Decker","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.eururo.2016.08.037_bib0510","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1093\/annonc\/mdv356","article-title":"High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers","volume":"26","author":"Castro","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0515","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1073\/pnas.89.8.3367","article-title":"Mendelian inheritance of familial prostate cancer","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2016.08.037_bib0520","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2016.08.037_bib0525","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2016.08.037_bib0530","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrurol.2013.266","article-title":"The genetic epidemiology of prostate cancer and its clinical implications","volume":"11","author":"Eeles","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0735","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0540","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0545","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/gim.2013.193","article-title":"Prostate cancer incidence in males with Lynch syndrome","volume":"16","author":"Haraldsdottir","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0550","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0555","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0560","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1464-410X.2011.10292.x","article-title":"Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer","volume":"109","author":"Gallagher","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.08.037_bib0565","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.08.037_bib0570","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"key":"10.1016\/j.eururo.2016.08.037_bib0575","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2016.08.037_bib0580","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2016.08.037_bib0585","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.08.037_bib0590","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2016.08.037_bib0595","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2016.08.037_bib0600","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/emboj.2009.206","article-title":"PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination","volume":"28","author":"Bryant","year":"2009","journal-title":"EMBO J"},{"key":"10.1016\/j.eururo.2016.08.037_bib0605","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.eururo.2016.08.037_bib0610","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2016.08.037_bib0615","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccr.2011.04.010","article-title":"Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer","volume":"19","author":"Brenner","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2016.08.037_bib0620","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1073\/pnas.0914242107","article-title":"Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair","volume":"107","author":"Kumar","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2016.08.037_bib0625","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","article-title":"Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM","volume":"75","author":"McCabe","year":"2015","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.eururo.2016.08.037_bib0630","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2016.34.15_suppl.5010","article-title":"Co-targeting androgen receptor (AR) and DNA repair: a randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +\/\u2212 the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)","volume":"34","author":"Hussain","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0635","first-page":"1","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"2045","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0640","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0645","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0650","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.08.037_bib0655","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0660","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.08.037_bib0665","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0670","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0675","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"Suppl","key":"10.1016\/j.eururo.2016.08.037_bib0680","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/jco.2013.31.15_suppl.2580","article-title":"First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors","volume":"31","author":"de Bono","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0685","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1535-7163.MCT-12-0813","article-title":"Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer","volume":"12","author":"Ihnen","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2016.08.037_bib0690","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s10637-014-0099-0","article-title":"Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Hussain","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.eururo.2016.08.037_bib0695","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.037_bib0700","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","article-title":"An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib","volume":"11","author":"Mateo","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0705","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-14-0173","article-title":"Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP","volume":"12","author":"Chao","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.eururo.2016.08.037_bib0710","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial","volume":"27","author":"Sternberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0715","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.037_bib0720","first-page":"1","article-title":"Efficacy of chemotherapy in BRCA1\/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study","volume":"44","author":"Ang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.08.037_bib0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.08.037_bib0730","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816305048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816305048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:06:02Z","timestamp":1759583162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816305048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0302283816305048"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.08.037","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA Repair in Prostate Cancer: Biology and Clinical Implications","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}